Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven A Grover

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|May 8, 2004
Health-related quality of life in cardiac patients with dyslipidemia and hypertensionLyne Lalonde, Annette O'Connor, Lawrence Joseph, et al.
The Canadian Journal of Cardiology|May 10, 2007
Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia?Steven A Grover, Louis Coupal, Mohammed Kaouache, et al.
The Canadian Journal of Cardiology|February 28, 2021
Gambling With Cardiovascular Disease Risk Models: How to Choose and How to UseSteven A Grover, Hiba Jekki, Mohammed Kaouache, et al.
Archives of Internal Medicine|October 28, 2009
Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levelsSteven A Grover, Mohammed Kaouache, Lawrence Joseph, et al.
The American Journal of Medicine|August 2, 2003
Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factorSteven A Grover, Louis Coupal, Hanna Zowall, et al.
Archives of Internal Medicine|February 13, 2003
The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?Steven A Grover, Vivian Ho, Frédéric Lavoie, et al.
The Canadian Journal of Cardiology|July 9, 2005
Cost-effectiveness of lipid-lowering treatment according to lipid levelLouise Pilote, Vivian Ho, Frédéric Lavoie, et al.
Journal of Occupational and Environmental Medicine|December 5, 2017
The Measurable Benefits of a Workplace Wellness Program in Canada: Results After One YearIlka Lowensteyn, Violette Berberian, Patrick Belisle, et al.
Pharmacotherapy|August 12, 2004
Development and preliminary testing of a patient decision aid to assist pharmaceutical care in the prevention of cardiovascular diseaseLyne Lalonde, Annette M O'Connor, Elizabeth Drake, et al.
Open Forum Infectious Diseases|February 15, 2022
Outpatient Therapies for COVID-19: How Do We Choose?Todd C Lee, Andrew M Morris, Steven A Grover, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|May 8, 2004
Health-related quality of life in cardiac patients with dyslipidemia and hypertensionLyne Lalonde, Annette O'Connor, Lawrence Joseph, et al.
The Canadian Journal of Cardiology|May 10, 2007
Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia?Steven A Grover, Louis Coupal, Mohammed Kaouache, et al.
The Canadian Journal of Cardiology|February 28, 2021
Gambling With Cardiovascular Disease Risk Models: How to Choose and How to UseSteven A Grover, Hiba Jekki, Mohammed Kaouache, et al.
Archives of Internal Medicine|October 28, 2009
Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levelsSteven A Grover, Mohammed Kaouache, Lawrence Joseph, et al.
The American Journal of Medicine|August 2, 2003
Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factorSteven A Grover, Louis Coupal, Hanna Zowall, et al.
Archives of Internal Medicine|February 13, 2003
The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?Steven A Grover, Vivian Ho, Frédéric Lavoie, et al.
The Canadian Journal of Cardiology|July 9, 2005
Cost-effectiveness of lipid-lowering treatment according to lipid levelLouise Pilote, Vivian Ho, Frédéric Lavoie, et al.
Journal of Occupational and Environmental Medicine|December 5, 2017
The Measurable Benefits of a Workplace Wellness Program in Canada: Results After One YearIlka Lowensteyn, Violette Berberian, Patrick Belisle, et al.
Pharmacotherapy|August 12, 2004
Development and preliminary testing of a patient decision aid to assist pharmaceutical care in the prevention of cardiovascular diseaseLyne Lalonde, Annette M O'Connor, Elizabeth Drake, et al.
Open Forum Infectious Diseases|February 15, 2022
Outpatient Therapies for COVID-19: How Do We Choose?Todd C Lee, Andrew M Morris, Steven A Grover, et al.
Pageof 4